Trial reportThe New England journal of medicine2013
Low-intensity therapy in adults with Burkitt's lymphoma.
Trial report in The New England journal of medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 161 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Adults and Children With Previously Untreated Patients With Aggressive Non-Hodgkin's Lymphoma
Short-Course EPOCH - Rituximab in Untreated CD-20+ HIV-Associated Lymphomas
Who cites it
161 citing papers in PubMed, 5 syntheses or guidelines pooled it, 358 citations in OpenAlex.
- Comparison of chemotherapy regimens plus rituximab in adult Burkitt lymphoma: A single-arm meta-analysis.Frontiers in oncology · 2022Pooled it
- Pooled it
- Burkitt and Burkitt-Like Lymphomas: a Systematic Review.Current oncology reports · 2020Pooled it
- Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma.Annals of oncology : official journal of the European Society for Medical Oncology · 2015Pooled it
- A new prognostic score for AIDS-related lymphomas in the rituximab-era.Haematologica · 2014Pooled it
- Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia.Leukemia & lymphoma · 2023Trial
- Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma.Haematologica · 2021Trial
- Dose-adjusted EPOCH-R in patients with newly diagnosed diffuse large B-cell lymphoma harboring MYC rearrangement.Journal of clinical and experimental hematopathology : JCEH · 2020Trial
- Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.The Lancet. Haematology · 2018Trial
- Time to treatment is an independent prognostic factor in aggressive non-Hodgkin lymphomas.British journal of haematology · 2018Trial
- Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707.Haematologica · 2017Trial
- Trial
- Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma.Haematologica · 2016Trial
- Trial
- Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.British journal of haematology · 2014Trial
- Comparison of outcomes after DA-EPOCH-R or GMALL high-intensity therapy for front-line treatment of Burkitt lymphoma: A retrospective cohort.British journal of haematology · 2026Article
- Primary Burkitt lymphoma of the breast in a young north African woman: diagnostic challenge and benefit of early intensive chemotherapy.Oxford medical case reports · 2026Article
- [Chinese expert consensus on the diagnosis and treatment of Burkitt lymphoma (2026)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- Case Report: Synchronous Manifestations of Kaposi Sarcoma Herpesvirus-Associated Disorders.Cancer reports (Hoboken, N.J.) · 2026Article
- Treatment of Burkitt lymphoma in real-world setting: findings on 104 consecutive cases diagnosed and treated in Kazakhstan over the last decade.Annals of hematology · 2026Article
101 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundBurkitt's lymphoma is an aggressive B-cell lymphoma that occurs in children and adults and is largely curable with the use of intensive and toxic chemotherapy. Current treatments are less effective and have more severe side effects in adults and patients with immunodeficiency than in children.
methodsWe studied low-intensity treatment consisting of infused etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (EPOCH-R) in patients with untreated Burkitt's lymphoma. Two EPOCH-R regimens were tested: a standard dose-adjusted combination in human immunodeficiency virus (HIV)-negative patients (DA-EPOCH-R group) and a lower-dose short-course combination with a double dose of rituximab in HIV-positive patients (SC-EPOCH-RR group).
resultsA total of 30 consecutive patients were treated; 19 patients were in the DA-EPOCH-R group, and 11 in the SC-EPOCH-RR group. The overall median age of the patients was 33 years, and 40% were 40 years of age or older; 73% of the patients had intermediate-risk disease, and 10% had high-risk disease. The principal toxic events, fever and neutropenia, were observed during 22% of the DA-EPOCH-R treatment cycles and 10% of the SC-EPOCH-RR treatment cycles. The tumor lysis syndrome developed in 1 patient; no treatment-related deaths occurred. The median cumulative doses of doxorubicin-etoposide and cyclophosphamide administered in the SC-EPOCH-RR group were 47% and 57% lower, respectively, than those administered in the DA-EPOCH-R group. With median follow-up times of 86 months in the DA-EPOCH-R group and 73 months in the SC-EPOCH-RR group, the rates of freedom from progression of disease and overall survival were, respectively, 95% and 100% with DA-EPOCH-R and 100% and 90% with SC-EPOCH-RR. None of the patients died from Burkitt's lymphoma.
conclusionsIn this uncontrolled prospective study, low-intensity EPOCH-R-based treatment was highly effective in adults with sporadic or immunodeficiency-associated Burkitt's lymphoma. (Funded by the National Cancer Institute; ClinicalTrials.gov numbers, NCT00001337 and NCT00006436.).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.